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Competing interests. None declared. 
  
With great interest we read the viewpoint from Prof. Landewé,1 calling for more caution, 
research, and debate regarding the risks of overdiagnosis and overtreatment in 
rheumatology. Strongly agreeing with the overall message, especially that "(...) 
overtreatment is hardly discussed but likely present", we would like to contribute to this 
discussion by raising an issue that touches base on two paradigms listed by Prof. 
Landewé: remission and evidence-based rheumatology. 
There is now ample evidence that a substantial proportion (12 to 38%) of patients with 
rheumatoid arthritis (RA) does not achieve the status of remission according to disease 
activity indices, solely because of a patient global assessment (PGA) score >1 (0 to 10 
scale, 10=worst).2 3 If the elevated score on PGA does not reflect disease activity, 
additional immunosuppressive agents cannot improve the status of these patients, as 
inflammation is already essentially abrogated. Elevated PGA, therefore, may induce the 
risk of overtreatment when applying disease indices or Boolean-based criteria to define 
the treatment aim, which is remission or at least at low disease activity (LDA) according to 
current treatment recommendations.4 5 Naturally, patients who still report relevant 
disease symptoms despite the absence of significant inflammation need to be 
appropriately assessed and supported to address disease impact, but this probably calls 
for adjuvant interventions, rather than reinforcement of immunosuppressive therapy.6 7  
This has led to our recent proposal that the management of RA should be guided by a dual 
treat-to-target strategy (dual T2T): one representing the control of inflammation 
(biological remission) and the other the control of disease impact (symptom remission).8 
Remission of inflammation often also results in symptom remission, but not always.2 8 
Given that the relationship between PGA and disease activity is not consistent, especially 
around the cut-offs of disease activity indices for LDA and remission,8 it is proposed that 
the definition of biological remission should not include PGA, but that it should be defined 
by the number of swollen and tender joints and CRP, i.e. 3-variable remission. This 
proposition is further supported by the evidence that, overall, PGA is driven by multiple 
factors beyond inflammation9 10, including non-inflammatory pain, limitation in physical 
function, fatigue, depression, and comorbidities,2 8 as well as by socio-economic and 
cultural factors.11 Recent research has demonstrated that patients vary enormously in 
their interpretation of the question and as many as 40% of them find scoring of PGA 
confusing.12 13 This is accrued by the existence of several different formulations of PGA, 
which, in itself, may influence the remission rate in 4.7 to 6.3%14. 
Symptom remission, an important outcome from patient’s perspective,15 16 would, in this 
proposal, be served better by an instrument capable of measuring and discriminating the 
underlying causes of on-going disease impact, so as to guide the selection of appropriate 
interventions. Currently, the best-suited instrument for this purpose seems to be the 
Rheumatoid Arthritis Impact of Disease score (RAID)17 18 with its seven domains, 
individually considered adequate to guide treatment decisions.18 Whatever the instrument 
chosen, treatment decisions must always be based on two-way communication and shared 
decision-making between the patient and the caring team.19 
We believe that this novel strategy, i.e. dual T2T and the use of 3-variable remission and 
RAID, would significantly reduce the risk of overtreatment. Step-up of treatment 
strategies according to recommendations would still be used until biological remission is 
achieved. If, at this stage, symptom remission is not achieved, adjuvant therapy may be 
considered, according to the most affected domains of impact according to RAID. Actually, 
these domains of impact should be considered from the beginning, not only because 
patient well-being is a core objective of treatment but also because some of them, e.g. 
depression, may actually diminish the probability of achieving the biological target.20 
It has been argued that "the remission criteria are designed for research and for optimum 
specificity, and not for use in treat‐to‐target schemes",21 but this does not preclude their 
frequent use in clinical settings. It has also been put forward that “most rheumatologists in 
practice do not need new instruments to decide which patients are most likely have 
residual disease and are in need of switching their treatment as opposed to patients with 
comorbidities that confound the interpretation of their RA symptoms”.22 Prof. Landewé 
argues, conversely, that "sometimes (...) guidelines are too rigidly pursued by clinicians 
who may ignore the needs of individual patients".1 In fact, the EULAR recommendations 
for the management of RA state that treatment must be based on a shared decision with 
patients and that decisions on immunosuppressive treatment should take structural 
damage, comorbidities or contraindications into account.4 The risk of overtreatment 
would be further diminished if recommendations specifically address major aspects that 
may “confound” the practicing rheumatologist.  
We believe that the proposal presented herein represents an important step forward in 
this direction. It also highlights the need to keep the patients’ perspective and needs at the 
bull’s eye of the treatment target, underlining the importance of an holistic approach to 
patient assessment and treatment, in order to achieve optimal results.19 In clinical trials, 
the improved relationship between the 3-variable disease index/remission criteria and 
disease activity would result in a more accurate determination of the actual efficacy and 
value of disease-modifying medications.  
Additional evidence is needed to fully support this paradigm shift, namely by investigating 
whether exclusion of PGA negatively affects the relationship between remission and 
structural damage progression – the crunch of the matter, after all. Work is underway.23 
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